Immunologic effects of recombinant interferon-gamma in patients with renal cell carcinoma.

概要

論文の詳細を見る
Immunologic and antitumor effects of human recombinant interferon-gamma were studied in patients with renal cell carcinoma. A daily dose of 6 to 12×106 units/m2 of interferon-gamma was given by intravenous drip infusion or intramuscular injection to nine patients over a period varying from two to 16 weeks. Antibody-dependent cell-mediated cytotoxicity and OKIal-positive monocytes count increased significantly after the therapy was started. Interferon-gamma transiently increased OKT3- and OKT4-positive lymphocyte count. Tumor regression was not observed when clinical response was evaluated in seven patients. Two others, who had no measurable metastases, were not evaluated, because interferongamma were given to them as post-operative adjuvant therapy. Our results indicate that interferongamma stimulated monocytes and enhanced cell-mediated cytotoxicity; they also suggest the necessity of combining monoclonal antibodies and other biological response modifiers that effect tumor-associated antigens.
The Keio Journal of Medicineの論文